Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

22.69
Delayed Data
As of May 31
 +0.69 / +3.11%
Today’s Change
19.59
Today|||52-Week Range
71.50
-63.36%
Year-to-Date
Better Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc.
May 31 / MotleyFool.com - Paid Partner Content
Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
May 26 / TheStreet.com - Paid Partner Content
3 Value Stocks Near 52-Week Lows Worth Buying
May 27 / MotleyFool.com - Paid Partner Content
Why Abercrombie & Fitch, Ionis Pharmaceuticals, and Movado Group Slumped Today
May 26 / MotleyFool.com - Paid Partner Content
Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
May 27 / Zacks.com - Paid Partner Content
Why Alnylam Pharmaceuticals, Inc. Competed Higher Today
May 26 / MotleyFool.com - Paid Partner Content
Ionis Pharmaceuticals (IONS) Stock Falls, BMO Downgrades on GlaxoSmithKline Trial Del...
May 27 / TheStreet.com - Paid Partner Content
Cramer: Avoid Sloppiness by Watching Your Stock Table Manners
May 26 / TheStreet.com - Paid Partner Content
Analysts' Actions -- Deckers, Palo Alto Networks, Signet Jewelers, Workday and More
May 27 / TheStreet.com - Paid Partner Content
Why Ionis Pharmaceuticals Plummeted Today
May 26 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close22.01
Today’s open22.29
Day’s range21.71 - 23.18
Volume5,906,811
Average volume (3 months)2,223,143
Market cap$2.7B
Dividend yield--
Data as of 3:59pm ET, 05/31/2016

Growth & Valuation

Earnings growth (last year)-124.24%
Earnings growth (this year)-100.62%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+32.47%
P/E ratioNM
Price/Sales26.13
Price/Book13.19

Competitors

 Today’s
change
Today’s
% change
INCRINC Research Holding...-1.70-3.76%
PRAHPRA Health Sciences ...-0.11-0.23%
NKTRNektar Therapeutics+0.27+1.78%
PRXLPAREXEL Internationa...+0.15+0.24%
Data as of 3:59pm ET, 05/31/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)-$0.47
Annual revenue (last year)$283.7M
Annual profit (last year)-$88.3M
Net profit margin-31.12%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Stanley T. Crooke
Chief Operating Officer &
Director
B. Lynne Parshall
Corporate headquarters
Carlsbad, California

Forecasts

Partner Offers

Search for Jobs